Anocca AB, a Swedish developer of T cell receptor-engineered T cell (TCR-T) cell therapies, has appointed Christiane Hanke-Harloff to its board. With a career in biotechnology, pharmaceutical, and CDMO, Dr Hanke-Harloff will support the company’s strategy to progress its TCR-T cell therapies into clinical development for hard-to-treat cancers. She is currently on the boards of InnoCore Pharmaceuticals BV and Ascenion GmbH and previously held executive roles at Gilead Sciences and Gedeon Richter. Dr Hanke-Harloff has a PhD in molecular biology from the Max Planck Institute of Biochemistry in Martinsried, Germany. Earlier this year, Anocca made a licensing agreement for the use of EmendoBio’s gene editing technology and received a GMP licence for its cell-therapy manufacturing facility, the largest in the Nordics.
Anocca announced the appointment on 31 May 2024.
Copyright 2024 Evernow Publishing Ltd